Skip to content

Registry for Vascular Anomalies Associated With Coagulopathy

International Registry for Vascular Anomalies Associated With Coagulopathy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00576888
Acronym
VAC
Enrollment
30
Registered
2007-12-19
Start date
2007-11-30
Completion date
2019-04-05
Last updated
2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneovisceral Angiomatosis With Thrombocytopenia, Hemangiomas, Multifocal Lymphangioendotheliomatosis With Thrombocytopenia, Vascular Anomaly With Thrombocytopenia

Keywords

Multifocal lymphangioendoltheliomatosis with thrombocytopenia, Cutaneovisceral angiomatosis with thrombocytopenia, Thrombocytopenia, Hemangiomas, Hemangiomatosis, Lymphatic malformation, Kasabach-Merritt, Blue-rubber bleb nevus, Angiomatosis

Brief summary

PURPOSE The purpose of this study is to learn more about multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT). MLT is a rare vascular disorder characterized by multiple congenital skin and visceral lesions, profound thrombocytopenia, and gastrointestinal bleeding. The skin lesions may appear red, brown or blue, often misdiagnosed as hemangiomas. The gastrointestinal tract, liver, and lungs are the most common internal organs involved. The severe thrombocytopenia (low platelets) is believed to be the result of platelet trapping within the skin and visceral vascular lesions. Severe and chronic gastrointestinal bleeding is common during infancy and early childhood. Although a relatively newly described entity, MLT was likely previously reported as hemangiomas, blue rubber bleb nevus syndrome, diffuse hemangiomatosis, Kasabach-Merritt phenomenon, and hereditary hemorrhagic telangiectasia. The term cutaneovisceral angiomatosis with thrombocytopenia is also a term used for this same disease. This study is a longitudinal cohort study of MLT to collect detailed clinical data on the distribution of disease, disease severity, and complications. This data will be used to create diagnostic criteria and an evaluation protocol for infants with this disease

Detailed description

After informed consent is obtained a detailed question will be mailed to participating patients and families. This questionnaire will also be available electronically through an educational website. Data collected will include photographs of skin lesions, video images of gastrointestinal lesions, demographic data, clinical information, therapeutic interventions, glass slides of tissue biopsies, and collection of DNA. Enrollment will be patient family driven and modeled after several successful registries of rare diseases.

Interventions

OTHERno intervention

no intervention - observational only

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Subjects with a vascular anomaly with coagulopathy

Exclusion criteria

* Subjects without a vascular anomaly with coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with genetic mutations, copy number variations and/or expression analysisAfter DNA collected and batches are sent for analysisExpand knowledge on consensus diagnostic criteria, atypical presentations and long term outcomes of patients with vascular anomalies

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026